Phase 1 study

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Incyte Corporation
Registry number NCT07195916
Started 8 January 2026 Today 16 October 2026 Estimated completion 18 August 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Macquarie University Hospital Sydney NSW Recruiting
Princess Alexandra Hospital Australia Woolloongabba QLD Recruiting
Cancer Research Sa Adelaide SA Recruiting
Peter Maccallum Cancer Centre-Royal Melbourne Hospital Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 280

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Age ≥18 years.

* ECOG performance status of 0 or 1.

* Histologically confirmed:

* Clear cell renal cell carcinoma (ccRCC).

* Diffuse large B-cell lymphoma (DLBCL, NOS).

* High-grade B-cell lymphoma (HGBCL).

* Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).

* Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).

* Disease progression, relapse, or refractory to prior therapy:

* ccRCC: ≥1 prior line incl. ICI + TKI.

* DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.

* PTCL/CTCL: ≥1 prior systemic therapy.

* Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).

* Tumor tissue available for central testing.

Exclusion Criteria:

* Untreated or progressive CNS disease unless previously treated and stable.

* Other active invasive malignancy within 2 years (except certain low-risk cancers).

* Prior CD70-targeting therapy, including CAR T.

* ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.

* Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).

* Primary immunodeficiency or active autoimmune disease requiring immunosuppression.

* Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.

* Pregnancy, breastfeeding, or unwillingness to use effective contraception.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Dates on the record

Started 8 January 2026
Estimated completion 18 August 2028
Registry last updated 9 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 9 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.